API | darifenacin

darifenacin (enablex) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Now

Darifenacin is a selective muscarinic receptor M3 antagonist which was approved by FDA for the treatment of overactive bladder. ^NCATS

Chemistry

SMILES: NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1
InChIKey: HXGBXQDTNZMWGS-RUZDIDTESA-N
Mol. Mass: 426.56
ALogP: 3.96 Partition coefficient
ChEMBL Molecules:

darifenacin

darifenacin hydrobromide

More Chemistry

Pharmacology

Mechanisms of Action:
- Muscarinic acetylcholine receptor M2 (Homo sapiens) ^UniProt
- Muscarinic acetylcholine receptor M3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$2.1044 - $12.5103

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

darifenacin | darifenacina | darifenacine | darifénacine | darifenacin hydrobromide | darifenacin hydrochloride | darifenacinum | darifenicin | emselex | enablex | oxybutynin darifenacin | (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide | uk-88525 | uk-88525-04

Organizations (30)

Research & Development (16)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (15)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (2)

Urinary Bladder, Overactive (approved 2004)

Urinary Incontinence, Urge

Experimental Indications - Clinical Trial Phases 1-4 (8)

Drugs, Generic (Phase 1)

Healthy Volunteers (Phase 4)

Multiple Sclerosis (Phase 2)

Nocturia (Phase 4)

Spinal Cord Injuries (Phase 4)

Urinary Bladder (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Urinary Incontinence (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 19
# of Trial Organizations: 16

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue